Questions about this study?
The HopeStage team will email you.
Recruitment unclearEUCTR 2019-003343-29
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE 2)
This historical record does not confirm current site availability.
Historical research recordMultiple countries
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Bulgaria · Croatia and 6 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Recruitment unclear
- Enrollment listed in the registry
- 426
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Bulgaria, Croatia, Czechia, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2019-003343-29
- Official title
Show the full official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE 2)
Recruitment & locations
Status unknownBulgaria · Croatia · Czechia
5 more locations
- Hungary
- Italy
- Lithuania
- Poland
- Spain
Registry details
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is ACADIA Pharmaceuticals Inc.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
“Double blind, placebo-controlled study of efficacy, safety and tolerance of raloxifene as an adjuvant treatment for negative symptoms of schizophrenia in postmenopausal women” Estudio doble ciego...
"Estudio comparativo, randomizado y de grupos paralelos con PET en pacientes esquizofrénicos de nuevo diagnóstico en tratamiento con Aripiprazol y Risperidona"